Lilly Q3 Results - Q3 Top Pharma Company Earnings Reports
View Lilly's Q3 Earnings Report
FiercePharma says: Lilly posted $941.8 million in third-quarter net income, way up from last year's $465.6 million loss on charges. More impressively, however, the company managed to boost sales by 6.8 percent during a quarter when its rivals had a tough time on the revenue side.. Read more of our coverage here...
Highlights:
- Higher volume drives revenue growth
- Stronger dollar results in improved gross margin
- Earnings per share increase to $.86 (reported) or $1.20 (pro forma non-GAAP)
- Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (reported) or $4.30 - $4.40 (pro forma non-GAAP)
Check out Lilly's current earnings estimates from CNN Money
Lilly's Website: http://www.lilly.com/
Related Articles:
Lilly juggles jobs for emerging-markets growth
Cost-conscious Medco pits Plavix against Effient
Lilly's promo deal with CVS draws fire
Lilly offloads 700-worker Indiana plant
More stories about Eli Lilly
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: